Literature DB >> 24042176

Association between tissue characteristics evaluated with optical coherence tomography and mid-term results after paclitaxel-coated balloon dilatation for in-stent restenosis lesions: a comparison with plain old balloon angioplasty.

Takeshi Tada1, Kazushige Kadota, Shingo Hosogi, Koshi Miyake, Hideo Amano, Michitaka Nakamura, Yu Izawa, Shunsuke Kubo, Tahei Ichinohe, Yusuke Hyoudou, Haruki Eguchi, Yuki Hayakawa, Suguru Otsuru, Daiji Hasegawa, Yoshikazu Shigemoto, Seiji Habara, Hiroyuki Tanaka, Yasushi Fuku, Harumi Kato, Tsuyoshi Goto, Kazuaki Mitsudo.   

Abstract

AIMS: Morphological assessment of neointimal tissue using optical coherence tomography (OCT) is important for clarifying the pathophysiology of in-stent restenosis (ISR) lesions. The aim of this study was to determine the impact of OCT findings on recurrence of ISR after paclitaxel-coated balloon (PCB) dilatation compared with plain old balloon angioplasty (POBA). METHODS AND
RESULTS: Between July 2008 and May 2012, we performed percutaneous coronary intervention for 214 ISR lesions using POBA + PCB (146 lesions, PCB group) or POBA only (68 lesions, POBA group). Morphological assessment of neointimal tissue using OCT, including assessment of restenotic tissue structure and restenotic tissue backscatter, was performed. We examined the association between lesion morphologies and mid-term (6-8 months) results including ISR and target lesion revascularization (TLR) rates. Both ISR and TLR rates of lesions with a homogeneous structure were significantly lower in the PCB group than those in the POBA group (ISR: 20.0 vs. 55.6%, P = 0.002, TLR: 12.7 vs. 37.0%, P = 0.019), but there was no difference between the two groups in ISR and TLR rates of lesions with a heterogeneous or layered structure. Both ISR and TLR rates of lesions with high backscatter were significantly lower in the PCB group than those in the POBA group (ISR: 19.8 vs. 52.5%, P < 0.001, TLR: 13.6 vs. 42.5%, P = 0.001), but there was no difference between the two groups in ISR and TLR rates of lesions with low backscatter.
CONCLUSION: Morphological assessment of ISR tissue using OCT might be useful for identifying ISR lesions favourable for PCB dilatation.

Entities:  

Keywords:  in-stent restenosis lesion; optical coherence tomography; paclitaxel-coated balloon

Mesh:

Substances:

Year:  2013        PMID: 24042176     DOI: 10.1093/ehjci/jet165

Source DB:  PubMed          Journal:  Eur Heart J Cardiovasc Imaging        ISSN: 2047-2404            Impact factor:   6.875


  4 in total

Review 1.  Vascular Lesion-Specific Drug Delivery Systems: JACC State-of-the-Art Review.

Authors:  David Marlevi; Elazer R Edelman
Journal:  J Am Coll Cardiol       Date:  2021-05-18       Impact factor: 24.094

2.  Effect of drug-coated balloon angioplasty on in-stent restenotic coronary lesions analyzed with optical coherence tomography and serial coronary artery angioscopy.

Authors:  Naotaka Akutsu; Akihito Ogaku; Yutaka Koyama; Hidesato Fujito; Yasunari Ebuchi; Suguru Migita; Tomoyuki Morikawa; Takehiro Tamaki; Takashi Mineki; Takaaki Kougo; Keisuke Kojima; Korehito Iida; Nobuhiro Murata; Toshihiko Nishida; Toru Oshima; Mitsumasa Sudo; Daisuke Kitano; Hironori Haruta; Daisuke Fukamachi; Tadateru Takayama; Takafumi Hiro; Atsushi Hirayama; Yasuo Okumura
Journal:  Heart Vessels       Date:  2019-06-15       Impact factor: 2.037

3.  In-stent restenosis assessed with frequency domain optical coherence tomography shows smooth coronary arterial healing process in second-generation drug-eluting stents.

Authors:  Takashi Kajiya; Hiroshi Yamaguchi; Junichiro Takaoka; Kengo Fukunaga; Ryoichi Arima; Akihiro Miyamura; Toshiko Ninomiya; Nobuhiko Atsuchi; Yoshihiko Atsuchi; Mitsuyasu Terashima; Hideaki Kaneda; Mitsuru Ohishi
Journal:  Singapore Med J       Date:  2018-04-10       Impact factor: 1.858

4.  Comparative assessment of the antirestenotic efficacy of two paclitaxel drug-eluting balloons with different coatings in the treatment of in-stent restenosis.

Authors:  Freek Nijhoff; Pieter R Stella; Maartje S Troost; Anouar Belkacemi; Hendrik M Nathoe; Michiel Voskuil; Mariam Samim; Pieter A Doevendans; Pierfrancesco Agostoni
Journal:  Clin Res Cardiol       Date:  2015-11-05       Impact factor: 5.460

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.